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Abstract 21 
Background: Despite a higher prevalence of psychosocial morbidity in Inflammatory Bowel 22 
Disease (IBD), the association between depressive state and disease course in IBD is poorly 23 
understood.  24 
Aims:  Investigate the impact of depressive state on disease course in IBD. 25 
Methods: We conducted a systematic review in MEDLINE, EMBASE, the Cochrane Database 26 
of Systematic Reviews and PsychINFO for prospective studies evaluating the impact of 27 
baseline depressive state on subsequent disease course in adult IBD. 28 
Results: Eleven studies matched our entry criteria, representing 3194 patients with IBD. 29 
Three reported on patients with ulcerative colitis (UC), four included patients with Crohn's 30 
disease (CD) exclusively, and 4 studies included both UC and CD. Five studies reported an 31 
association between depressive state and disease course. None of the UC-specific studies 32 
found any association. In 3 of 4 CD-specific studies, a relationship between depressive state 33 
and worsening disease course was found. In 4 of 5 studies including patients in remission at 34 
baseline, no association between depressive state and disease course was found. Pooled 35 
analysis of IBD studies with patients in clinical remission at baseline identified no association 36 
between depressive state and disease course (HR 1.04, 95%CI 0.97-1.12). 37 
Conclusion:  There is limited evidence to support an association between depressive state 38 
and subsequent deterioration in disease course in IBD, but what data exists is more 39 
supportive of an association with CD than UC. Baseline disease activity may be an important 40 
factor in this relationship. Further studies are needed to understand the relationship 41 
between mental health and outcomes in IBD.  42 
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Introduction 43 
Inflammatory bowel disease (IBD), comprising ulcerative colitis (UC) and Crohn's disease 44 
(CD), causes chronic inflammation predominantly affecting the gastrointestinal tract. There 45 
is considerable morbidity with a requirement for surgical intervention in up to 16% and 47% 46 
at 10 years in UC and CD respectively.1 As a result, patients with IBD experience 47 
substantially reduced health-related quality of life compared with healthy adults of similar 48 
age.2,3 Furthermore, depression is almost twice as common amongst patients with IBD when 49 
compared with healthy controls.4 The causality of the link between psychological wellbeing 50 
and disease course in IBD is poorly understood. There is emerging literature that a 51 
depressive state may impact adversely on disease course in IBD, but this has not been 52 
systematically reviewed. 53 
The underlying causes of IBD remain unknown but the higher prevalence of depression in  54 
patients with IBD has led to the suggestion that neuropsychiatric distress may significantly 55 
modify disease course.5 There is some evidence to suggest that psychological stress may 56 
impact upon neuro-enteric pathways, mediating and enhancing gastrointestinal 57 
inflammation.6,7 In animal studies, chemical induction of depression in a rodent model for 58 
IBD was associated with colitis reactivation.8 In humans, the influence of a variety 59 
psychological states on disease course in IBD, including anxiety, acute experimental stress, 60 
life-event stress and perceived stress have been previously reported.9,10,11,12,13,14 The results 61 
from these studies are conflicting, perhaps as a consequence of the marked heterogeneity 62 
in study design, varied definition of psychological exposure and wide-ranging quantification 63 
of disease outcomes. Data from retrospective population-based studies has indicated a 64 
possible association between the presence of depression and an increased risk of surgery in 65 
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CD, although difficulties arise when interpreting the potential confounding effect of disease 66 
severity on the risk of developing a depressive illness.15 Cross-sectional studies have 67 
reported a varied correlation between a depressive state and disease outcomes, but these 68 
are limited by their inability to assess this relationship temporally.9,16 Additionally, it remains 69 
difficult to distinguish whether psychological stress worsens disease course, or in fact 70 
worsening disease course alters psychological wellbeing.17 This is an important question to 71 
resolve since it has significant implications for how we treat IBD patients with medical and 72 
psychological therapies. Previous systematic reviews have evaluated the relationship 73 
between IBD and anxiety and/or depression.4,18 A small review by Maunder et al. that 74 
summarised the available literature characterising the longitudinal relationship between a 75 
variety of psychological stressors and disease activity, included only 4 studies describing the 76 
impact of a baseline depressive state on subsequent clinical outcomes.19 To our knowledge, 77 
no systematic reviews currently exist specifically focusing on the evidence base of 78 
prospective studies addressing the impact of baseline depressive state on subsequent 79 
disease course in IBD. 80 
We hypothesised that a depressive state could impact adversely on subsequent disease 81 
course in IBD. We therefore aimed to systematically summarise and review the existing 82 
literature on the impact of a depressive state on subsequent disease course in adult patients 83 
with IBD, restricting our searches to prospective studies to enable analysis of any temporal 84 
association between the two variables. We further aimed to perform a meta-analysis of UC 85 
and CD studies, where suitable publications were available, to quantify the direction and 86 
size of any effect in this potential relationship.  87 
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Methods 88 
We used the PRISMA statement (see supplementary files), an internationally agreed peer-89 
approved 27-point check list for reporting systematic reviews, to develop our own protocol 90 
and also consulted the methodology of a broader review of psychological factors in IBD.20,21  91 
Search terms and data sources 92 
We searched multiple electronic databases including MEDLINE (1946 to September 2016), 93 
EMBASE (1974 to September 2016), Cochrane Library and PsychINFO (1967 to September 94 
2016). Additionally, we conducted hand searches of the reference lists of relevant review 95 
articles. 96 
A combination of Medical Subject Headings (MeSH) terms and free text were used to 97 
generate the following search algorithm: (inflammatory bowel disease OR Crohn's disease 98 
OR ulcerative colitis) AND (depression OR depressive illness OR low mood OR depressive 99 
disorder OR depression symptoms) AND (disease activity OR disease flares OR disease 100 
symptoms). This was entered into the database search engines to generate the initial list of 101 
publications to be searched (EndNote™, Thompson Reuters, Toronto)  102 
Study inclusion and exclusion criteria 103 
Studies were selected for inclusion if they attempted to characterise the impact of a 104 
depressive state at study entry on subsequent disease course in adult patients with IBD. 105 
Only prospective cohort studies were included as we hypothesised a causal relationship 106 
between exposure to a depressive state and outcome. We only included studies reported in 107 
the English language.  108 
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Research including children or adolescents up to the age of 18 years were excluded as 109 
paediatric IBD is often considered as a separate entity in both clinical and research fields, 110 
particularly as it has a different, usually more aggressive disease course.22 Secondly, it is 111 
likely that the psychological profile of children and adolescents with IBD is different from 112 
their adult counterparts. Current evidence suggests depression is less prevalent in younger 113 
patients with IBD.23,24  114 
All studies included patients with IBD based on established clinical, histological and 115 
radiographic criteria. These included studies with solely CD or UC patients, or both,  116 
accepting that patients with CD may experience more depression than UC patients.4 We 117 
included studies irrespective of baseline disease activity at entry into the study, but sub-118 
categorised our results by whether study entrants were in remission, had active disease or 119 
were unselected for disease activity at study enrolment. 120 
We included studies that measured a depressive state (including symptoms of depression) 121 
of participants at entry into the study using a recognised diagnostic instrument. These 122 
included the Beck Depression Inventory (BDI), the Hospital Anxiety and Depression Score 123 
(HADS) and the Patient Health Questionnaire 9 (PHQ-9),  Global Severity Index symptom 124 
checklist 90R (GSI), or where depressive symptoms were screened for as part of a broader 125 
assessment of psychological state. We did not exclude patients on anti-depressant 126 
medications as it remains largely unclear if these medications impact on IBD course 127 
independently, but we documented it when they were used. 128 
Our primary outcome was disease course. Acknowledging that there is a limited amount of 129 
research in this field, and thus not wanting to restrict the scope of the review, we have used 130 
this term to include a range of measures of disease outcomes, including recognised clinical, 131 
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blood and endoscopic surrogate markers of disease activity. Under the umbrella term of 132 
disease course, we included studies that quantified disease outcomes with clinical scoring 133 
tools such as the Crohn's Disease Activity Index (CDAI) or Harvey Bradshaw Index in CD, and 134 
Mayo Score or Colitis Activity Index (CAI) in ulcerative colitis.  We also considered any 135 
research that defined outcomes using objective markers of inflammation including blood 136 
and faecal markers (including calprotectin), and/or endoscopic or histological findings. We 137 
also accepted studies reporting increased medication requirements as a surrogate marker 138 
for worsening disease course, for example the need for steroids, requirement for rescue 139 
therapy (the use of agents such as ciclosporin or biologic therapies to avoid imminent 140 
surgery) or IBD-related surgery. Finally, we excluded any study that exclusively used patient-141 
reported symptoms to quantify disease activity, for example survey-based studies. This was 142 
to minimise the potential confounding from gastrointestinal symptoms originating from co-143 
existing functional bowel disorders that can occur in the absence of active intestinal 144 
inflammation.25 This did not eliminate certain commonly used clinical scoring systems such 145 
as the CDAI, that contain a component of patient-reported symptoms in the score. Where 146 
available we noted whether the scoring systems were patient or physician reported.  147 
Data extraction and synthesis 148 
Two reviewers (CA and SK) independently screened the complete list of publications 149 
between September and December 2015. Subsequently, searches were updated to include 150 
additional relevant publications up to September 2016. Duplicate publications were 151 
removed and the remaining titles and abstracts were screened for inclusion into the review, 152 
against pre-determined criteria: 1) human study including patients with IBD; 2) English 153 
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language; 3) addressing psychological symptoms in patients with IBD and; 4) assessment of 154 
disease course.  155 
Relevant data from each study were extracted, including study design, population size and  156 
characteristics, IBD disease type, measures of depressive state, IBD disease course measures 157 
and time frame. After scrutinising each potential paper against our inclusion/exclusion 158 
criteria detailed above, the final list of included research papers was generated. A third 159 
reviewer (RP) was used to resolve any discrepancies by discussion. Each of the final papers 160 
were appraised for quality and bias using the Critical Appraisal Skills Program (CASP) 161 
checklist for cohort studies.26 We adapted a scoring system based on the 6 quality criteria 162 
questions in section A of the CASP checklist: 1) Did the study address a clearly focused 163 
question? 2) Was the cohort recruited in an acceptable fashion and was there any issue with 164 
selection bias? 3) Was exposure measured using a validated tool? 4) Was the outcome 165 
measured using a validated tool? 5) Have the authors identified and adjusted for 166 
confounding factors appropriately? 6) Was follow up of and study completion of entrants 167 
adequate? All papers were graded by both reviewers against each of the quality indicators 168 
and scored accordingly giving a maximum of 6 points and a minimum of zero points per 169 
paper (one point per criteria achieved). We set a score of 0-2 as poor in quality, 3-4 as 170 
moderate in quality, and 5-6 as good in quality. 171 
 Statistical analysis 172 
We subsequently performed a meta-analysis to quantify the direction and effect size of the 173 
impact of a depressive state on disease progress. We only included studies with UC or CD 174 
patients who were in remission at study entry, and reported outcomes as Hazard Ratios 175 
(HR). HR estimating the impact of a depressive state on subsequent disease progress were 176 
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extracted from each of the relevant studies. The pooled HR with 95 % confidence intervals 177 
(CIs) was calculated using the log hazards ratio and standard error. We used the most 178 
adjusted HR published in the respective studies. Where appropriate, if depression scores 179 
were stratified by severity, we included data for the most severe depression cohort in the 180 
quantitative analysis. 181 
Initially, we analysed UC and CD studies separately, and then pooled all appropriate IBD 182 
studies in a further sub-analysis. The Dersimonian-Laird random effects model was used to 183 
calculate the pooled HR as it is unclear if there is a single true effect that underpins all of the 184 
studies.27 The Cochrane test  and the I2 statistic were calculated to quantify heterogeneity 185 
between included studies within the analysis. A p-value of less than 0.10 was considered as 186 
the cut-off for presence of statistical heterogeneity. For the I2 statistic, a threshold of 50% or 187 
above was considered to represent substantial heterogeneity. All calculations for the 188 
quantitative analysis were performed on  Review Manager (RevMan) Version 5.3. 189 
(Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014).  190 
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Results 191 
Summary of searches 192 
Our electronic searches identified 1097 potentially eligible studies for screening after 193 
removal of duplicates and addition from the manual searches (Figure 1). Thirty-four texts 194 
were considered for full evaluation and data extraction. Eleven papers met our inclusion 195 
criteria representing a total of 3194 patients with IBD, with 4840 person years of follow-up 196 
(calculated as number of persons per study multiplied by the mean follow-up time 197 
contributed per study). Six papers originated from Europe, 4 from North America, and one 198 
from Australasia. In total, 3 studies examined patients with UC (see supplementary Table 1) 199 
and 4 studies analysed only patients with CD (supplementary Table 2). A further 4 studies 200 
included patients with UC and  CD together (supplementary Table 3). Bubble charts were 201 
subsequently generated to graphically present study year, effect direction and study size. 202 
The bubble charts were further sub-categorised by disease sub-type and baseline disease 203 
activity (Figure 2/Figure 3).   204 
Studies addressing the impact of a depressive state on subsequent disease course in UC 205 
 We identified three prospective studies that attempted to define the association between a 206 
depressive state and disease course in UC.28,29,30 All three studies included patients who 207 
were deemed to be in steroid-free clinical remission at study entry. Depressive state was 208 
assessed  in each of the studies alongside a number of other psychological characteristics; 209 
perceived stress28,29,30, stressful life experiences 28,29 and anxiety.30 All three studies used 210 
different tools to categorise a depressive state; the Centre for Epidemiological Studies 211 
Depression Scale (CES-D)28, the Symptom checklist 90R (SCL-90R)29, and the Hospital Anxiety 212 
and Depression Score (HADS)30.  All three used disease exacerbation/relapse as the primary 213 
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outcome, however, each used separate instruments to define disease exacerbation/relapse: 214 
scoring systems based on clinical and endoscopic findings developed for the study28,29 and 215 
the Colitis Activity Index.30 Relapse rate was similar in all three studies (between 37%-44%). 216 
None of the authors found a significant association between baseline depressive state and 217 
subsequent deterioration in disease course in patients with UC (see supplementary Table 1). 218 
Studies addressing the impact of a depressive state on subsequent disease course in CD 219 
We identified four studies that specifically investigated the impact of a depressive state on 220 
disease course in patients with CD (see supplementary Table 2).31,32,33,34 There was 221 
considerable heterogeneity in the disease status of patients at entry to study; two studies 222 
enrolled patients who were unselected for disease activity at baseline31,34, one study 223 
included only patients in clinical remission at baseline33, and one study specifically included 224 
patients with active disease as defined by the Crohn's disease activity index (CDAI)32.  All 225 
four studies used different tools to categorise a depressive state;  the Beck Depression 226 
Inventory (BDI)31, the Patient Health Questionnaire 9 (PHQ-9)32, the SCL-90R 33, and HADS 34. 227 
All four studies used the CDAI to quantify disease activity in patients, although one study 228 
used response to infliximab as the primary outcome.32 Relapse rates, where identifiable, 229 
were 22-37%. Three of the papers identified a significant association between a depressed 230 
state and subsequent disease activity. Mardini et al found a strong positive association 231 
between BDI scores and disease activity at both current and next 2 clinic visits (week 8 and 232 
week 12). Each unit increase in BDI correlated to a 6 unit increase in CDAI at next visit 233 
(p=0.0004). Persoons et al reported a significantly lower 4 week response rate to infliximab 234 
in patients with CD diagnosed with a major depressive disorder (MDD) at baseline compared 235 
patients without MDD(29% vs 70%, p<0.001). In the multivariate analysis, MDD was also 236 
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associated with failure to achieve remission (OR 0.17, 95% CI 0.05-0.57, p=0.004) and an 237 
increased risk of subsequent retreatment with infliximab in long-term (HR 2.27, 95% CI 1.36-238 
3.79, p=0.002). Lastly, Camara et al, demonstrated that the depressive component of 239 
perceived stress was significantly associated with a subsequent deterioration in disease 240 
course (OR for flare of disease - 1.78 95% CI 1.38-2.28, p<0.001). 241 
 Studies addressing the impact of a depressive state on subsequent disease course in IBD 242 
(either UC or CD) 243 
We identified four studies that included both patients with UC and CD (see supplementary 244 
Table 3). 35,36,37,38 Three of the studies entered patients with UC or CD at enrolment 245 
unselected for baseline disease activity.35,37,38 The fourth study only considered patients in 246 
clinical remission.36 Two studies characterised depressive state with BDI, and two studies 247 
used the HADS.37,38 The CDAI for CD patients, and the CAI/SCCAI in UC were used to 248 
measure disease course in two of the papers36,37. A disease assessment tool developed by 249 
the authors was used in the third study.35 The final study constructed a disease assessment 250 
tool that combined surrogate clinical parameters of disease course (increased medication 251 
use, development of complicated disease, requirement for surgery) and disease activity 252 
scores (CDAI in CD and Modified Truelove and Witts Activity Index (MTWAI) in UC).38 With 253 
respect to analysing the impact of a depressive state on disease course, two of the studies 254 
published combined results for patients with IBD (CD and UC). The other two studies 255 
analysed CD and UC separately, and in combination.35,38 Two of the studies found no 256 
association between a depressive state and subsequent risk of disease exacerbation.35,37 257 
However, Mittermaier et al reported that higher BDI scores at baseline was associated with 258 
the development of a flare, the number of flares, and inversely with time to flare 259 
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(independent of baseline disease activity scores).36 As CD and UC patients were not analysed 260 
separately, no comment could be made about this finding with respect to the disease 261 
subgroups, a point made by the authors in their discussion. However, it is also noted that 262 
almost 80% of the participants had CD in this study. Mikocka-Walus et al also reported that 263 
depression was associated with a shorter time to disease relapse in patients with IBD, 264 
compared to patients without depression (log rank test for trend p<0.0001).38 These 265 
findings were maintained in the sub-analysis of patients with CD and UC, although the effect 266 
was more pronounced in patients with CD (log rank test for trend p=0.0007 in CD, p=0.005 267 
in UC). 268 
Results of the pooled analysis 269 
Four studies qualified for entry into the pooled analysis (Figure 4). Three studies were 270 
included in the subgroup analysis for patients with UC in remission at baseline.28,29,30 Pooled 271 
analysis of HR showed no significant impact of baseline depressive state on subsequent 272 
disease course in these patients (pooled HR 1.02, 95%CI: 0.97-1.08). Heterogeneity of 273 
included studies was low (Cochrane Q test = 1, p=0.61, I2 = 0%). There were too few studies 274 
to assess for publication bias using funnel plots. Only one study was suitable for analysis in 275 
the subgroup analysis of patients with CD in remission at baseline.33 Again, there was no 276 
effect of baseline depression on subsequent disease course in these patients (HR 1.60, 95% 277 
CI: 0.92-2.77). A combined analysis of all suitable studies also did not indicate any significant 278 
effect between depressive state and disease course (HR1.04, 95% CI: 0.97-1.12). 279 
Quality and validity of studies 280 
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A detailed breakdown of the Oxford CASP quality assessment scores for all eleven studies is 281 
provided (see supplementary table 4). Only one of the 11 studies met all 6 criteria for 282 
quality.36 Six studies were scored as good quality, and 5 studies as moderate quality. No 283 
studies were scored as low quality using the CASP appraisal tool. 284 
Although all the studies addressed the impact of a depressive status on a measurement of 285 
disease course, ten of the 11 studies assessed depressive state alongside multiple other 286 
clinical and psychological parameters. Only one paper examined depressive state as the 287 
unique exposure.32 288 
All the studies would have been prone to referral centre bias, with the probable exception 289 
of Camara et al and Mikocka-Walus et al, who recruited study patients from multiple 290 
hospitals and clinics nationally, and together enrolled more patients than all the other nine 291 
studies combined.34,38 Although there was marked heterogeneity in the instruments used to 292 
assess a depressive state, all 11 studies used validated tools for this purpose. Eight of the 293 
eleven studies used accepted tools for measuring disease course such as CDAI or CAI.  294 
Although the three oldest studies didn't use such tools, which may reflect the era of these 295 
studies, all three used detailed and robust methods including clinical and/or endoscopic 296 
parameters as surrogate markers of disease activity.28,29,35 Only four studies included 297 
endoscopic parameters in the assessment of outcomes. 28,29,30,35 Three papers did not take 298 
in to account IBD-specific medication use at study enrolment which may be considered a 299 
confounding factor with regards to subsequent disease course.35,37,38 300 
Furthermore, three studies included patients on concurrent antidepressant medication 301 
(ADM).29,31,32 Although the impact of ADM is yet to be determined in subsequent disease 302 
course in IBD, the inclusion of patients on psychotropic medication into a study where 303 
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depression is a defining exposure, may be confounding. In fact, only the one study by 304 
Mittermaier et al, actively excluded such patients from study entry.36 305 
Study follow-up length was varied, but all the studies bar Persoons et al had follow up for at 306 
least a year.32 We considered a follow up period of at least a year as a satisfactory time 307 
period for capturing subsequent changes in disease course, given the appreciable risk of a 308 
disease flare over this time period for both UC and CD.39,40 However, it is still difficult to 309 
draw true conclusions on the time lag of any potential effect of a depressive state on 310 
subsequent disease course. By contrast, Persoons et al used 4 weeks as the time span to 311 
assess disease course in response to a baseline depressive state (using the surrogate marker 312 
of response to infliximab treatment). Although this is a short follow up in comparison to the 313 
other studies, it should not be discounted, as arguably the patients in this study had a more 314 
severe disease phenotype with active inflammation at entry and most having previously 315 
used biologic therapy. 316 
317 
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Discussion 318 
To our knowledge this is the first systematic review to examine the association between a 319 
depressive state and its subsequent impact on disease course in adult IBD. Of the 11 studies 320 
included, five suggested an association between a baseline depressive state and worsening 321 
disease course31,32,34,36,38, but six failed to show association.28,29,30,33,35,37  322 
In this review, we found greater evidence to suggest that a depressive state in CD may be 323 
associated with a subsequent deterioration in disease course than in UC. Three of the four 324 
studies that included only patients with Crohn's disease, and five of the eight studies (63%) 325 
that included patients with CD suggested an association between a depressive state and 326 
worsening disease course, manifest as either increased CDAI, poorer response to biologic 327 
therapy, or risk of flare. By contrast, only two of seven studies that included patients with 328 
UC reported an association between depression and disease activity in UC. None of the 329 
three studies that considered only patients with UC showed any association between a 330 
depressive state and disease course. Furthermore, in four out of 5 studies in which patients 331 
at study entry were in disease remission, no association between baseline depressive state 332 
and subsequent worsening of disease course was found.  333 
By contrast, two thirds of the studies that included patients with active IBD at baseline 334 
reported an association between baseline depressive state and disease course 335 
deterioration. In the pooled meta-analysis of studies, including UC and CD patients in 336 
remission, no significant association was identified (HR 1.04 95% CI: 0.97-1.12). Further 337 
analysis of sub-groups found no significant association patients with UC, and in the one 338 
study of patients with CD  suitable for inclusion also found no significant association. 339 
17 
 
It is difficult to draw concrete conclusions on the time frame for a worsening of IBD among 340 
patients with depression as all the studies were of different lengths and had different 341 
follow-up times. Hence the time frame may be a reflection on the duration of the study 342 
rather than the true time frame between depression and worsening of IBD. 343 
The findings of this review suggest that there may be a differential effect of depression on 344 
outcomes between IBD subtypes. Other researchers have observed similar associations with 345 
poor mental health. Ananthakrishnan et al reported in a retrospective population-based 346 
study that the risk of surgery was significantly increased in patients with CD and a co-morbid 347 
diagnosis of major depressive disorder, whereas UC patients with major depressive disorder 348 
had no increased risk of colectomy.15 349 
Although there was a lack of randomised controlled or empirical studies in this review, the 350 
quality of the individual prospective studies included was moderate to good (CASP validity 351 
score range 3-6). Despite this, we identified several limitations in the available literature. 352 
Firstly, as most of the studies recruited patients from a single clinic or hospital, the 353 
probability of selection and referral centre bias is increased. The relatively small number of 354 
patients in most of the studies made it more difficult to draw firm conclusions, particularly 355 
as only two studies (Mikocka-Walus et al (2008) and Camara et al) included appropriate 356 
power calculations in their methodology. Secondly there was a heavy reliance on using 357 
symptom scores for depression, which may not accurately reflect the true presence of 358 
clinical depression. For example, the HADS has a sensitivity and specificity of only 80% for 359 
predicting depression.41 The use of more than one depression screening tool, or a formal 360 
clinical psychiatric evaluation of patients selected for studies, may improve the 361 
identification of patients with true depressive illness. Furthermore, there was considerable 362 
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variation between the studies as to the accepted cut-off values used to define cases of 363 
depression. Mikocka-Walus et al used a HADS >7 to define cases, whereas Langhorst et al 364 
used a cut-off of HADS>10. The use of non-validated tools for measuring disease activity 365 
may have been an issue in some of the earlier studies, but the current availability of clinical, 366 
biochemical, endoscopic and histological markers of disease activity means that this should 367 
not be a problem in future prospective studies.  368 
The strengths of this review include the comprehensive and systematic approach to 369 
evaluating the available research in this field. Also, by including only prospective studies, it 370 
enabled a more robust approach in addressing the true impact of a depressive state on 371 
subsequent disease course, without the limitations encountered in retrospective and cross-372 
sectional studies. There are limitations to this review that require discussion. We excluded 373 
texts that were not published in English, and thus relevant non-English studies may have 374 
been left out. This might also mean that certain populations were not represented 375 
appropriately, although we did identify studies from three separate continents. We also 376 
acknowledge that our search algorithm, although detailed, may not be fully comprehensive 377 
for all relevant studies. Of note, we only included the three terms 'disease activity', 'disease 378 
flares' and 'disease symptoms' in our search, and perhaps including additional terms for 379 
outcomes such as 'disease course', 'IBD course' and 'disease outcomes' would have added a 380 
further level of confidence in the search. Furthermore, we excluded findings reported only 381 
in abstract, which may have removed relevant studies. We have attempted to minimize the 382 
potential confounding effect of functional gastrointestinal symptoms by accepting into the 383 
review recognised and validated tools to measure disease activity. Whereas clinical scoring 384 
systems such as the CDAI are relatively easy to administer and are frequently used in clinical 385 
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studies, we appreciate that some of these tools may overestimate the true burden of active 386 
IBD, as they rely in some part on subjective patient-reported symptomology, which may be 387 
functional in origin. The CDAI has a reasonable reliability and validity,42 but against the 388 
emerging gold standard of mucosal assessment as a measure of assessing disease activity, it 389 
does not correlate well.43 Interestingly, the studies that did include endoscopic assessment 390 
failed to find an association between baseline depressive state and subsequent 391 
deterioration in disease course. Future studies addressing this research question may need 392 
to consider focusing on harder objective endpoints given the potential limitation of patient-393 
reported symptoms.  394 
We also acknowledge that our definition of a depressive state is broad, and that true 395 
depression is not a dichotomous entity. In this review, a variety of assessment methods and 396 
screening tools were utilised in the included studies. As with the IBD clinical-based activity 397 
scores, screening tools for depression are advantageous because of their simplicity, low cost 398 
and acceptable sensitivity. However, research on depression screening tools in other chronic 399 
illness have highlighted issues with overall validity and reliability.44  Ideally, the diagnosis of 400 
depression for the purposes of this research question would be made following objective 401 
assessment by a mental health specialist.  402 
Because of the heterogeneity of the studies included, the subsequent meta-analysis was 403 
limited to only three studies in patients with UC in remission at study entry, and one 404 
including patients with CD. Although in the UC sub-analysis heterogeneity amongst the 405 
included studies was low, the analysis only included 213 patients, from a total of 3194 406 
patients in all studies (~6%). Therefore, it is difficult to draw more general conclusions 407 
regarding the impact of a depressive state on disease course in IBD. However, amongst 408 
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patients with UC who are in remission at baseline, depressive state appears not to influence 409 
subsequent disease course. 410 
The idea that a depressive state may impact on clinical outcomes in IBD taps into the 411 
complex inter-relationship between psychological stressors and systemic inflammation.6 412 
There is some biological plausibility given that acute psychological stress has been 413 
demonstrated to lead to changes in inflammatory constituents at a cellular level in both 414 
animal and human models of IBD.8,10 Conversely, inflammation may also promote 415 
depression through the up-regulation of inflammatory cytokines and intermediates.45  416 
Whether small changes at a cellular level in response to psychological stress actually 417 
translate to an objective increase in clinical markers of disease activity is more difficult to 418 
establish. Of the eleven prospective studies identified in this review, five provided evidence 419 
for an association between a depressive state and worsening disease course. Research from 420 
cross-sectional studies generally conclude a correlation between depression and worsening 421 
disease activity but cannot account for any temporal association between the exposure and 422 
outcome.9,46,47 A large prospective survey-based study also reported that depressive 423 
symptoms were associated with an increased risk of patient-reported disease activity.48 424 
Patients who experience an improvement in disease activity also suffer less from depressive 425 
symptoms.17 Furthermore, a link between a depressive state in human subjects and 426 
deteriorating disease activity has been postulated in various non-gastrointestinal 427 
inflammatory conditions including rheumatoid arthritis and ankylosing spondylitis,49,50 but 428 
not in others such as systemic lupus erythematosus.51 429 
Depression is estimated to affect between 7-59% of patients suffering with IBD,4 and may 430 
independently worsen health related quality of life irrespective of disease severity.52 The 431 
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finding that a depressive state may potentially alter disease course opens up the possibility 432 
of a variety of new treatment options in IBD. Depression is readily treatable with 433 
antidepressant medications (ADM). In a rodent model of IBD, chemically-induced depression 434 
treated with desipramine was associated with an improvement of the colitis.8 Using ADMs 435 
to treat inflammatory conditions may not be limited to just IBD. Research in rheumatoid 436 
arthritis indicated both fluoxetine and citalopram improved disease activity in rodent 437 
models.53 However, the role of such medications as therapeutic agents in patients with IBD 438 
remains to be fully evaluated. A small retrospective study has suggested a possible 439 
therapeutic benefit of ADMs in IBD reporting that patients treated with ADMs had fewer 440 
steroid courses in follow up.54 Conversely, a systematic review including 12 non-randomised 441 
studies that assessed the efficacy of ADMs in IBD was inconclusive.55 However, a recent 442 
systematic review by Macer et al., incorporating a broad range of study designs including 443 
both prospective and retrospective studies, reported evidence of a positive effect of ADMs 444 
in 12 of the fifteen studies included.56 A recent meta-analysis of 14 randomised controlled 445 
trials by Gracie et al. assessed the impact of psychological therapies on disease activity, 446 
mood and quality of life in patients with IBD.57 Interestingly, although psychological 447 
therapies appeared to improve depression and quality of life in the short term, no effect on 448 
disease activity indices was found when compared to controls with inactive disease.  449 
In light of the unclear impact of ADMs on the course of IBD, there have been calls to address 450 
this knowledge gap in the field and the first randomised controlled trials on the subject are 451 
currently being undertaken.58 A recently reported placebo controlled pilot study in 26 452 
patients with CD failed to show an impact of low dose fluoxetine on disease outcomes 453 
including CDAI scores and faecal calprotectin levels, although the results are difficult to 454 
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interpret due to small study numbers, relatively short follow-up time, and the inclusion of 455 
only patients in clinical remission at baseline.59 Further studies investigating this potential 456 
association are warranted. 457 
Irrespective of these findings, it may be advisable that patients with IBD are screened for 458 
depression (and other psychological disturbances) both at diagnosis and at subsequent 459 
follow-up. The link between psychological stressors and disease activity in IBD has been 460 
recognised in a number of national and international disease guidelines, of which many now 461 
recommend screening for concurrent psychological disorders in these patients.60 This 462 
strategy may be particularly pertinent for patients with CD, who are more likely to suffer 463 
from depression than those with UC, and possibly experience a worse disease course in the 464 
presence of a depressive state. Screening for psychological disorders can also highlight 465 
patients who require additional psychological support with cognitive therapy and/or specific 466 
psychological medications, which may enhance compliance with medications.  467 
In conclusion, this review has found limited evidence to support an association between 468 
depressive state and subsequent deterioration in disease course in IBD. But what data exits 469 
is more supportive of an association in patients with CD than UC. Baseline disease activity 470 
may be an important factor in this relationship. Study quality was variable and further 471 
studies are needed to understand the relationship between mental health and outcomes in 472 
IBD.  473 
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Figure 1: schematic of systematic review methodology and study inclusion for qualitative and 670 
quantitative analysis 671 
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Figure 2: Bubble chart demonstrating studies and study size stratified by IBD disease sub-type dichotomising if they support or refute a correlation 
between depressive state and subsequent disease course in IBD 
 
White circle - study including patients with ulcerative colitis (UC) only.  Black circle - study including patients with Crohn's disease (CD) only. Grey circle - study including patients with UC and 
CD. Diameter of circles representative of study size. Exact study size given below: 
1 - North et al 1991 (n=32),   2 - Levenstein et al 2000 (n=62),   3 - Bitton et al 2003 (n=60),   4 - Mittermeier et al 2004 (n=60),   5 - Mardini et al 2004 (n=18),   6 - Persoons et al 2005 (n=100),   
7 - Mikocka-Walus et al 2008 (n=66),   8 - Bitton et al 2008 (n=101),   9 - Camara et al 2011 (n=597),   10 - Langhorst et al 2013 (n=91),   11 - Mikocka-Walus et al 2016(n=2007) 
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Figure 3: Bubble chart demonstrating studies and study size stratified by disease activity at study entry dichotomising if they support or refute a 
correlation between depressive state and subsequent disease course in IBD 
 
Crossed circle - study including patients with IBD in remission at study entry. Empty circle - study including patients unselected for disease activity at study entry. Checked circle - study 
including patients with active disease at study entry. Diameter of circles representative of study size. Exact study size given below: 
1 - North et al 1991 (n=32),   2 - Levenstein et al 2000 (n=62),   3 - Bitton et al 2003 (n=60),   4 - Mittermeier et al 2004 (n=60),   5 - Mardini et al 2004 (n=18),   6 - Persoons et al 2005 (n=100),   
7 - Mikocka-Walus et al 2008 (n=66),   8 - Bitton et al 2008 (n=101),   9 - Camara et al 2011 (n=597),   10 - Langhorst et al 2013 (n=91),   11 - Mikocka-Walus et al 2016(n=2007) 
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Figure 4: quantitative analysis of the impact of a depressive state on disease course in patients with IBD who are in remission at baseline 
 
Legend:  
UC - ulcerative colitis  
CD - Crohn's disease 
SE - standard error  
33 
 
Section/topic  # PRISMA Checklist item  
Reported 
on page 
#  
TITLE   
Title  1 Identify the report as a systematic review, meta-analysis, or both.  1 
ABSTRACT   
Structured summary  2 Provide a structured summary including, as applicable: background; objectives; data sources; study 
eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; 
limitations; conclusions and implications of key findings; systematic review registration number.  
2 
INTRODUCTION   
Rationale  3 Describe the rationale for the review in the context of what is already known.  3,4 
Objectives  4 Provide an explicit statement of questions being addressed with reference to participants, interventions, 
comparisons, outcomes, and study design (PICOS).  
4 
METHODS   
Protocol and registration  5 Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if 
available, provide registration information including registration number.  
5 
Eligibility criteria  6 Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years 
considered, language, publication status) used as criteria for eligibility, giving rationale.  
5 
Information sources  7 Describe all information sources (e.g., databases with dates of coverage, contact with study authors to 
identify additional studies) in the search and date last searched.  
5 
Search  8 Present full electronic search strategy for at least one database, including any limits used, such that it 
could be repeated.  
5 
Study selection  9 State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if 
applicable, included in the meta-analysis).  
5,6,7 
Data collection process  10 Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and 
any processes for obtaining and confirming data from investigators.  
7,8 
Data items  11 List and define all variables for which data were sought (e.g., PICOS, funding sources) and any 
assumptions and simplifications made.  
6,7,8 
Risk of bias in individual 
studies  
12 Describe methods used for assessing risk of bias of individual studies (including specification of whether 
this was done at the study or outcome level), and how this information is to be used in any data 
synthesis.  
7,8 
34 
 
Summary measures  13 State the principal summary measures (e.g., risk ratio, difference in means).  8, 9 
Synthesis of results  14 Describe the methods of handling data and combining results of studies, if done, including measures of 
consistency (e.g., I
2
) for each meta-analysis.  
8, 9 
 
Page 1 of 2 
Section/topic  # Checklist item  
Reported 
on page #  
Risk of bias across 
studies  
15 Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, 
selective reporting within studies).  
9 
Additional analyses  16 Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if 
done, indicating which were pre-specified.  
9,10 
RESULTS   
Study selection  17 Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for 
exclusions at each stage, ideally with a flow diagram.  
29 
Study characteristics  18 For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-
up period) and provide the citations.  
Supplementary 
tables 1-3 
Risk of bias within 
studies  
19 Present data on risk of bias of each study and, if available, any outcome level assessment (see item 
12).  
Supplementary 
table 4 
Results of individual 
studies  
20 For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for 
each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.  
32 
Synthesis of results  21 Present results of each meta-analysis done, including confidence intervals and measures of 
consistency.  
32 
Risk of bias across 
studies  
22 Present results of any assessment of risk of bias across studies (see Item 15).  Supplementary 
table 4 
Additional analysis  23 Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see 
Item 16]).  
32 
DISCUSSION   
Summary of evidence  24 Summarize the main findings including the strength of evidence for each main outcome; consider their 
relevance to key groups (e.g., healthcare providers, users, and policy makers).  
16,17 
Limitations  25 Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete 
retrieval of identified research, reporting bias).  
18, 19 
35 
 
Conclusions  26 Provide a general interpretation of the results in the context of other evidence, and implications for 
future research.  
16-22 
FUNDING   
Funding  27 Describe sources of funding for the systematic review and other support (e.g., supply of data); role of 
funders for the systematic review.  
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